UnitedHealth Group (NYSE:UNH - Get Free Report) had its target price reduced by stock analysts at Barclays from $441.00 to $440.00 in a report issued on Wednesday, Benzinga reports. The brokerage presently has an "overweight" rating on the healthcare conglomerate's stock. Barclays's price objective would indicate a potential upside of 13.15% from the stock's previous close.
Several other analysts have also recently weighed in on UNH. Mizuho raised their price objective on shares of UnitedHealth Group from $470.00 to $493.00 and gave the company an "outperform" rating in a research report on Monday, July 20th. Deutsche Bank Aktiengesellschaft upped their target price on shares of UnitedHealth Group from $370.00 to $467.00 and gave the stock a "hold" rating in a research report on Friday, July 17th. The Goldman Sachs Group increased their target price on UnitedHealth Group from $435.00 to $490.00 and gave the company a "buy" rating in a research note on Friday, July 17th. UBS Group restated an "outperform" rating on shares of UnitedHealth Group in a research report on Tuesday. Finally, HSBC lifted their price target on UnitedHealth Group from $300.00 to $380.00 and gave the stock a "hold" rating in a research note on Monday, July 6th. Twenty investment analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat, UnitedHealth Group presently has a consensus rating of "Moderate Buy" and a consensus price target of $461.66.
View Our Latest Stock Report on UnitedHealth Group
UnitedHealth Group Price Performance
Shares of UNH traded up $11.10 during trading hours on Wednesday, reaching $388.86. 2,003,904 shares of the company's stock traded hands, compared to its average volume of 7,342,901. UnitedHealth Group has a 12 month low of $255.96 and a 12 month high of $461.62. The company has a current ratio of 0.78, a quick ratio of 0.78 and a debt-to-equity ratio of 0.66. The stock has a market cap of $349.03 billion, a PE ratio of 25.06, a price-to-earnings-growth ratio of 1.42 and a beta of 0.60. The firm's 50 day simple moving average is $387.44 and its 200-day simple moving average is $382.57.
UnitedHealth Group (NYSE:UNH - Get Free Report) last posted its quarterly earnings data on Tuesday, October 13th. The healthcare conglomerate reported $4.69 earnings per share for the quarter, topping the consensus estimate of $4.14 by $0.55. The company had revenue of $112.70 billion for the quarter, compared to analysts' expectations of $111.31 billion. UnitedHealth Group had a net margin of 3.14% and a return on equity of 16.53%. UnitedHealth Group's revenue for the quarter was down .4% compared to the same quarter last year. During the same period in the prior year, the business earned $2.59 earnings per share. UnitedHealth Group has set its FY 2026 guidance at 20.500- EPS. Equities analysts expect that UnitedHealth Group will post 19.85 EPS for the current year.
Insiders Place Their Bets
In other news, CEO Patrick Conway sold 1,169 shares of the stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $390.00, for a total transaction of $455,910.00. Following the completion of the sale, the chief executive officer owned 15,328 shares of the company's stock, valued at approximately $5,977,920. This represents a 7.09% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.19% of the company's stock.
Institutional Investors Weigh In On UnitedHealth Group
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. First Citizens Bank & Trust Co. boosted its position in UnitedHealth Group by 20.7% during the 3rd quarter. First Citizens Bank & Trust Co. now owns 21,294 shares of the healthcare conglomerate's stock valued at $7,817,000 after buying an additional 3,653 shares during the period. Focus Financial Network Inc. increased its position in shares of UnitedHealth Group by 0.9% in the third quarter. Focus Financial Network Inc. now owns 33,275 shares of the healthcare conglomerate's stock valued at $12,215,000 after acquiring an additional 298 shares during the period. My Personal CFO LLC increased its position in shares of UnitedHealth Group by 3.8% in the third quarter. My Personal CFO LLC now owns 1,269 shares of the healthcare conglomerate's stock valued at $466,000 after acquiring an additional 46 shares during the period. XY Planning Network Inc. boosted its holdings in shares of UnitedHealth Group by 4.3% during the third quarter. XY Planning Network Inc. now owns 2,277 shares of the healthcare conglomerate's stock worth $836,000 after purchasing an additional 93 shares during the period. Finally, Allied Investment Advisors LLC grew its stake in shares of UnitedHealth Group by 4.7% in the third quarter. Allied Investment Advisors LLC now owns 641 shares of the healthcare conglomerate's stock worth $235,000 after purchasing an additional 29 shares during the last quarter. 87.86% of the stock is currently owned by institutional investors.
UnitedHealth Group News Roundup
Here are the key news stories impacting UnitedHealth Group this week:
- Positive Sentiment: Strong Q3 beat and raised outlook: Adjusted earnings of $4.69 per share exceeded the roughly $4.14 consensus, while revenue of $112.7 billion also topped estimates. Operating profit increased 52%, supported by lower medical costs and better execution. UnitedHealth raised its 2026 adjusted EPS outlook to at least $20.50, above the approximately $19.86 analyst consensus. UnitedHealth Group tops estimates, hikes profit outlook as insurer manages high medical costs
- Positive Sentiment: Improving margins and efficiency: The medical care ratio improved to 88.4%, while management highlighted artificial-intelligence initiatives that reduce administrative work and clinical review times. Management also suggested Wall Street may be underestimating 2027 earnings potential and outlined longer-term earnings growth of 13% to 16%. UnitedHealth Q3 2026 Earnings Call Transcript
- Neutral Sentiment: Analyst views are mixed: Mizuho named UNH a top pick, but TD Cowen remained cautious. Robert W. Baird lowered its price target to $427 from $453 and maintained a neutral rating, signaling upside but less confidence in the recovery. UnitedHealth Stock Forecast: TD Cowen Stays Cautious Even as Mizuho Names UNH a Top Pick
- Negative Sentiment: Growth and business-mix concerns remain: Quarterly revenue declined slightly year over year, Optum Health revenue reportedly slipped, and UnitedHealth’s Medicare business exit is creating uncertainty around future membership and profitability. Investors also remain focused on Medicaid margins, which management expects to improve after 2026. UnitedHealth Group Drops 5.4% as Medicare Exit Clouds Q3 Beat
UnitedHealth Group Company Profile
(
Get Free Report)
UnitedHealth Group Incorporated NYSE: UNH is a diversified health care and well-being company serving individuals, employers, health care providers and government programs. Its operations are organized primarily through UnitedHealthcare and Optum.
UnitedHealthcare provides health benefit plans and services, including employer-sponsored coverage, individual and family plans, Medicare and Medicaid offerings, and other government-supported programs. Its services include health insurance administration, pharmacy benefits and care management.
Optum provides health care services, technology and data solutions, pharmacy services, and analytics to health plans, employers, government agencies, health care providers and consumers.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider UnitedHealth Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and UnitedHealth Group wasn't on the list.
While UnitedHealth Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.